Laidlaw assumed coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report sent to investors on Tuesday morning, The Fly reports. The firm issued a buy rating on the biotechnology company’s stock.
ARCT has been the topic of a number of other reports. Zacks Investment Research upgraded Arcturus Therapeutics from a hold rating to a buy rating and set a $5.25 target price on the stock in a report on Thursday, January 3rd. ValuEngine cut Arcturus Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Arcturus Therapeutics currently has an average rating of Buy and an average price target of $5.25.
Shares of NASDAQ ARCT opened at $5.05 on Tuesday. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $10.00.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Featured Article: Asset Allocation and Your Retirement
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.